title: Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer.
authors.affiliation: University of Alabama, Birmingham Comprehensive Cancer Center, Birmingham, AL.
authors.forename: Guru
authors.initials: G
authors.lastname: Sonpavde
authors.affiliation: Tisch Mt. Sinai Cancer Institute, New York, NY.
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Galsky
authors.affiliation: Michael E. DeBakey Veterans Affairs Medical Center and the Baylor College of Medicine, Houston, TX.
authors.forename: David
authors.initials: D
authors.lastname: Latini
authors.affiliation: Michael E. DeBakey Veterans Affairs Medical Center and the Baylor College of Medicine, Houston, TX.
authors.forename: Guoqing J
authors.initials: GJ
authors.lastname: Chen
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D055808:Drug Discovery; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin